Kariya Pharmaceuticals ApS: Financial statements 2020
CVR: 39270684
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
Kariya Pharmaceuticals ApS (CVR 39270684) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -1,493,450 and a net result of DKK -2,207,146 compared with DKK -7,304,278 the year before. Equity in the 2020 report amounted to DKK -9,511,324. The company had 2 employees in the financial year.
- Gross Profit
- DKK -1,493,450
- Profit/Loss
- DKK -2,207,146
- Equity
- DKK -9,511,324
- Total Assets
- DKK 1,683,281
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -1.5 mio. | -2.2 mio. | -9.5 mio. | 2 |
| 2019 | - | -6.3 mio. | -7.3 mio. | -7.3 mio. | 1 |
| 2018 | - | 0 | 0 | 100 | - |
Official annual report
How creditworthy is Kariya Pharmaceuticals ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
As of November 12, 2020, Christian Hölscher is registered as director of Kariya Pharmaceuticals ApS.
As of November 12, 2020, Ian Rodney Laquian has stepped down as director of Kariya Pharmaceuticals ApS.
Kariya Pharmaceuticals ApS has published its annual report for 2019. Gross profit came to DKK -6,324,847, and the net result was DKK -7,304,278.
About Kariya Pharmaceuticals ApS
Kariya Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in København N, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Kariya Pharmaceuticals IVS. The management consists of Christian Hölscher. The board consists of Ian Rodney Laquian (chair), Christian Hölscher, Claus Elsborg Olesen and John Connell. The company's owners include JUMIKA Holdings ApS, Thomsen Pharma ApS and MAC Clinical Research Finance Ltd.. The company has 0 employees (2025). In 2025, the company reported a gross profit of DKK -32,093,186 and a net result of DKK -26,490,250 compared with DKK -2,599,412 the year before. Equity in the 2025 report amounted to DKK -25,206,578.